# OnCo record sequoia (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/sequoia/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "sequoia", "NCT03336333" ;
  schema:name "SEQUOIA"@en ;
  schema:alternateName "SEQUOIA pegilodecakin"@en, "AM0010 phase 3"@en ;
  schema:description "Zanubrutinib beat chemoimmunotherapy in untreated CLL and delivered a 72% five-year progression-free rate in the hardest genetic subgroup."@en ;
  schema:url <https://onco.cc/trials/sequoia/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03336333>, <https://clinicaltrials.gov/study/NCT02923921>, <https://doi.org/10.1200/JCO.20.02232> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2017-10-31" ;
  onco:cancers <https://onco.cc/cancers/cll/>, <https://onco.cc/cancers/cll-treatment-naive/>, <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/metastatic-pdac/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:targets <https://onco.cc/targets/btk/> ;
  onco:drugs <https://onco.cc/drugs/zanubrutinib/>, <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/pegilodecakin/>, <https://onco.cc/drugs/folfox/> ;
  onco:companies <https://onco.cc/companies/eli-lilly/> ;
  onco:terms <https://onco.cc/terms/del17p-tp53/>, <https://onco.cc/terms/cold-vs-hot/>, <https://onco.cc/terms/pancreatic-failed-programmes/> ;
  onco:people <https://onco.cc/people/oyler-john/>, <https://onco.cc/people/constantine-tam/> .